Align Technology (ALGN) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenues: $1.048 billion, a 5.3% increase year-over-year and 5.2% sequentially.

Full Year Revenues: $4.0 billion, up 1% year-over-year.

Clear Aligner Revenues: $838 million in Q4, up 5.5% year-over-year; full year clear aligner revenues reached $3.2 billion, up 0.5% year-over-year.

Gross Margin: 65.3% in Q4, up 1.1 points sequentially but down 4.8 points year-over-year; non-GAAP gross margin was 72%.

Operating Margin: 14.8% in Q4, with a non-GAAP operating margin of 26.1%, both showing improvements year-over-year.

Net Income per Diluted Share: $1.89 for Q4, up from $1.39 sequentially and $1.39 year-over-year; non-GAAP EPS was $3.29.

Cash and Cash Equivalents: $1.095 billion as of December 31, 2025.

2Strategic Updates and Business Highlights

Record Clear Aligner Volumes: 677,000 cases in Q4, driven by growth in EMEA, Latin America, and APAC, with stability in North America.

DSO Partnerships: Continued strong growth with DSOs, which now represent about 25% of sales volume. Notable double-digit growth among top DSOs in the Americas.

Product Innovations: Advancements in direct fabrication and the introduction of products like Invisalign First and MAOB are expected to enhance market penetration.

Global Expansion: Significant growth in international markets, particularly in Latin America and APAC, with localized strategies tailored to specific regions.

3Forward Guidance and Outlook

Q1 2026 Revenue Guidance: Expected to be between $1.010 billion and $1.030 billion, representing a 3% to 5% year-over-year increase.

2026 Revenue Growth: Projected to grow by 3% to 4% year-over-year, with clear aligner volume growth expected to be in the mid-single digits.

Operating Margin Expectations: GAAP operating margin anticipated to be slightly below 18%, with non-GAAP operating margin around 23.7%.

Capital Expenditures: Expected to be between $125 million and $150 million for fiscal 2026.

4Bad News, Challenges, or Points of Concern

Market Softness in North America: Despite improvements, the North American retail market remains pressured, with some softness in consumer sentiment affecting patient inflow.

China's VBP Implementation Delays: Ongoing delays in the volume-based procurement process could impact future pricing and volume, although Align believes it is well-positioned to navigate these changes.

ASP Decline: Average selling prices are expected to decline by 1% to 2% year-over-year, influenced by geographic and product mix shifts.

Competitive Pressures: While competitors are raising prices, Align's guidance does not factor in these changes, indicating potential risks if the competitive landscape shifts significantly.

5Notable Q&A Insights

Volume Performance: CEO Joe Hogan highlighted that improved volume performance is attributed to both market stability and effective execution strategies, particularly with DSOs.

Adult Business Growth: The adult segment saw significant growth, attributed to successful DSO partnerships and enhanced financial options for patients.

DSO Growth Potential: Hogan indicated that DSOs are still in the early stages of adoption, suggesting ongoing opportunities for growth in this channel.

Direct Fabrication Impact: The transition to direct fabrication is expected to be margin dilutive initially but is seen as a long-term growth strategy.

Tax and Stimulus Impact: Align is not planning for any significant impacts from potential tax receipts or stimulus in their Q1 guidance. This summary encapsulates the key aspects of Align Technology's Q4 2025 earnings call, providing a clear overview of financial performance, strategic initiatives, and future outlook while addressing potential challenges and insights from the Q&A session.